| Ytd | 19.07% | |
| 1y | -22.66% |
| Open | 8.82 | Prev Close | 8.76 | Low | 8.43 | High | 8.82 | Mkt Cap | 252.24M |
| Vol | 0.00 | Avg Vol | 266.61K | EPS | -3.76 | P/E | -2.28 | Forward P/E | -5.54 |
| Beta | 0.63 | Short Ratio | 15.83 | Inst. Own | 27.85% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 04-30 | 50-d Avg | 8.50 | 200-d Avg | 7.54 | 1yr Est | 38.17 |
RNAC News
FREDERICK, Md., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “
Phase 3 AURORA trial of Descartes-08 in myasthenia gravis (MG) continues to advance; data expected i
FREDERICK, Md., July 02, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “
CZR, RNAC and NSP have been added to the Zacks Rank #5 (Strong Sell) List on July 1, 2026.
FREDERICK, Md., June 12, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) stock is up on Tuesday as the company is announcing a str
WestGene's established targeted LNP platform combined with Cartesian's mRNA payload from Descartes-0
Secured up to $150 million of non-dilutive financing from K2 HealthVentures; funding of $50 million
FREDERICK, Md., May 12, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “C
FREDERICK, Md., May 04, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “C
Cartesian Therapeutics, Inc. (RNAC) came out with a quarterly loss of $1.46 per share versus the Zac
Enrollment continues to progress in Phase 3 AURORA trial of Descartes-08 in myasthenia gravis Phase
Cartesian Therapeutics receives a buy rating, driven by a differentiated mRNA CAR-T approach for aut
Cartesian Therapeutics, Inc. (RNAC) was a big mover last session on higher-than-average trading volu
Cartesian Therapeutics, Inc. (RNAC) Presents at 25th Annual Needham Virtual Healthcare Conference Tr
FREDERICK, Md., April 02, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the
Cartesian Therapeutics, Inc. (NASDAQ: RNAC - Get Free Report) has been assigned an average rating of
Applied Therapeutics (NASDAQ: APLT - Get Free Report) and Cartesian Therapeutics (NASDAQ: RNAC - Get
Cartesian Therapeutics, Inc. (NASDAQ: RNAC - Get Free Report) has received an average rating of "Mod
Johnson & Johnson reported encouraging Phase 2 results for its experimental lupus drug nipocalim
The Dow Jones index closed higher by around 75 points on Monday. When insiders purchase or sell shar